Close Menu

Van Andel Research Institute

The company plans to use the funding to support commercial growth of its molecular drug-matching service, OncInsights, which provides a searchable treatment report to community oncologists.

The Neuroblastoma and Medulloblastoma Translational Research Consortium will conduct a 14-patient trial in which it will try to pinpoint treatments that best suit individual participants based on their gene expression profiles.

The trial, which has been approved by the Food and Drug Administration and will begin enrollment immediately, will use next-generation sequencing and gene expression analysis to provide information about a patient's disease state and to identify targets for therapy.

The Van Andel Research Institute has created a pediatric cancer research program that will use personalized medical approaches for translational research.

The patent covers a "high-throughput method of screening for a biomarker indicative of a disease" and includes "methods utilizing a microarray to measure the glycan level of a protein."

IP Roundup: Nov 30, 2010

Premium

Fluidigm, Expression Analytics, Maven Technologies, Van Andel Research Institute, Industrial Technology Research Institute, Northwestern University, Bio-Rad Laboratories, Illumina, Aperio Technologies, Samsung Electronics

The company's Multiplexing Diagnostics division will use the arrayer to develop molecular tools, including protein biomarkers, to diagnose allergy and autoimmunity.

Adoption of the platform will facilitate use of novel protein microarray formats developed at VARI as part of its research into blood tests to allow earlier detection and more accurate diagnosis of cancer.

Pages

A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.

The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.

Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.

In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.